...
首页> 外文期刊>Journal of cardiovascular electrophysiology >Five-year outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy
【24h】

Five-year outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy

机译:导管后的五年成果消融肥厚性心肌病患者的心房颤动

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Background Catheter ablation (CA) is a promising option in most patients with refractory atrial fibrillation (AF). However, data on over 5 years' outcomes with larger numbers in hypertrophic cardiomyopathy (HCM) patients with AF have not been reported. We assessed the outcome of 120 HCM patients following CA compared with a non-CA group and general patients without AF matched by HCM type with a 61.9 +/- 31.6-month follow-up. Methods and Results A total of 120 patients (age 61 +/- 9.8 years, female n = 43, 35.8%) with paroxysmal AF (n = 60, 50%) and persistent AF (n = 60, 50%) were enrolled. Of the 120 patients, 48 (40%) required redo procedures, and 82 (68.3%) were in sinus rhythm at the last evaluation. The composite clinical events rate following the initial CA was lower than that in the non-CA group (P = .023) and was also comparable to that in general patients without AF matched by HCM type (P = .729). Female (HR 2.358, 95% CI, 1.151-4.831; P = .019), NYHA functional class III-IV (HR 2.422, 95% CI, 1.032-5.685; P = .042) and left atrial diameter >= 50 mm (HR 3.319, 95% CI, 1.469-7.499; P = .004) were predictors of AF recurrence after multiple procedures. Conclusions CA was successful in restoring long-term sinus rhythm and improving symptomatic status in most HCM patients with refractory AF especially for those patients with small atrial size and mild symptoms. In addition, CA may contribute to the prevention of major clinical adverse events in the long-term clinical course.
机译:背景技术导管消融(CA)是大多数难治性心房颤动(AF)的患者中有前途的选择。然而,尚未报告超过5年的肥厚性心肌病(HCM)患者较大数量的数据。我们评估了CA后120患者的结果与非CA组和一般患者,无需通过HCM类型与HCM类型相匹配,其中61.9 +/- 31.6个月随访。方法和结果总共120名患者(61岁+/- 9.8岁,雌性N = 43,35.8%)征集阵发性AF(n = 60,50%)和持久性AF(n = 60,50%)。在120例患者中,48例(40%)所需的重做程序,82名(68.3%)在最后一次评价中窦性能。初始CA后的复合临床事件率低于非Ca组(P = .023),并且在没有通过HCM型匹配的情况下的普通患者中也与一般患者相当(P = .729)。女性(HR 2.358,95%CI,1.151-4.831; p = .019),Nyha功能III-IV(HR 2.422,95%CI,1.032-5.685; P = .042)和左心房直径> = 50 mm (HR 3.319,95%CI,1.469-7.499; p = .004)是多种程序后AF复发的预测因子。结论CA成功恢复长期窦性心律,并改善大多数HCM患者的症状状态,特别是对于那些小心房大小和轻度症状的患者。此外,CA可能有助于预防长期临床过程中的主要临床不良事件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号